Document:

Voice Mobility International, Inc.: Exhibit 10.6 - Filed by newsfilecorp.com

 

		EMPRISE CAPITAL CORP. 
	1600 - 609 Granville Street 
	P.O. Box 10068 Pacific Centre 
	Vancouver, BC V7Y 1C3 
	Main (778) 331-8505 
	Fax (604) 669-3877 tollfree fax 1(866)
      824-8938 

REPLY TO THE ATTENTION OF: Aron
Buchman
E-MAIL: abuchman@emprisecapital.com

July 6, 2010

Attention: Jay Hutton - Voice Mobility International,
Inc..

Subject: Proposal for Provision of Technical and Business
Advisory Services

Dear Jay,

Following our recent discussions, I am writing to set out the
terms under which Emprise Capital Corporation (“Emprise”) will be pleased to
provide Voice Mobility International, Inc. (“VMY”) Technical
and Business Advisory Services with respect to Operations, Strategic
Direction and securing of IP assets. 

During the course of this engagement, Emprise will provide:

	Technical and business advisory services; 

further detailed below in the Services section.

SERVICES

Understanding that the specific duties may vary within the
scope and duration of the engagement, in general Emprise expects to provide the
following services: 

TECHNICAL AND BUSINESS
ADVISORY SERVICES:

	Based on a review of the projected cash flows and discussions with
  management, identify strategic options and recommend to VMY a course of action
  to continue the commercialization or diversification of VMY Services Model;
  
	Assist VMY with undertaking a detailed technical evaluation of associated
  technologies to be deployed including advice relating to specific geographic
  industry legislation, technical specifications and risk evaluation;
  
	If appropriate, make strategic introductions or assist in negotiations
  with/to major corporate entities for possible joint ventures or OEM |
  Partnership opportunities;
  
	If appropriate, assist VMY with preparing the appropriate marketing
  documents (i.e. an Information Memorandum/Financing Plan) and make
  introductions to PR and Brand expertise, which will be used to solicit
  interest from potential investors, partners, acquirers or merger partners;
  
	If appropriate, initiate discussions with the qualified candidate(s) and
  co-ordinate all subsequent contacts, including arranging for signature of
  Confidentiality Agreements and coordinating the dissemination of information
  memoranda and other materials; 

	 
	www.emprisecapital.com 

	Assistance with the formal preparation of procedures and task lists to
  ensure that appropriate support is in place to manage risk and growth within
  but not limited to asset transfer, knowledge and business development
  activities;
  
	Carrying out such other similar activities as the Board of Directors of
  VMY may request from time to time; and
  
	Assume Roles and Title required by the VMY Board of Directors ; Directors
  will provide full indemnities and guarantees to ECC and Mr. A Buchman.
  
	Provide strategic advice and introductions to relevant parties based
  market conditions and current corporate initiatives being deployed. 

FEE
CALCULATION:

Emprise’s remuneration for the above services is as follows:

	 	1. 	
      A monthly fee in the amount of CDN$8,000 per month,
      payable to Emprise by VMY;

	 	 	 	 
	 		
      	

	
      Fee will be payable monthly, for services to be rendered
      for the month, commencing 7 July 2010;

	 	 	 	 
	 		
      	

	
      Upon execution Emprise will be eligible for a signing
      bonus equal to one month billing;

	 	 	 	 
	 		
      	

	
      If complexity, scope or demands of the role increases or
      decreases, the Fee will reflect the market value of the services performed
      as provided by an independent market assessment made and mutually agreed
      as an amendment to the said contract.

EXPENSES, TAXES AND
INTEREST

Emprise requires that all reasonable out of pocket costs,
charges and expenses, including travel, incurred by it in the performance of its
obligations under this mandate be reimbursed.

All or part of the amounts payable to Emprise pursuant to this
agreement may be subject to tax (including Goods and Services Tax and applicable
Provincial Sales Tax). Where such taxes are applicable, an additional amount
equal to the amount of such taxes owing will be charged to and be paid by VMY.

Any amounts due and payable hereunder and outstanding for in
excess of forty-five (45) calendar days shall accrue at the prevailing LIBOR one
month fixing rate for US$ plus six percent (6%), compounding on a monthly
basis.

ACKNOWLEDGEMENT

VMY acknowledges that:

EMPRISE shall be under no liability to VMY for, or as a result
of, its acting as technical, financial and business advisor to Competitors and
Clients, or the manner in which it resolves conflicts of interest deriving there
from, unless Emprise has acted in any manner which is dishonest or grossly
negligent.

REPORTING REQUIREMENTS

Emprise will report to VMY on a regular basis in such detail as
VMY may reasonably request in connection with Emprise’s performance of its
services hereunder.

VMY will provide to Emprise such information, documents, data,
advice, opinions and representations as Emprise may reasonably request relating
to any transaction that is the subject of this agreement. VMY represents and
warrants that any information furnished to Emprise will be true, accurate and complete in all material respects and
will not be misleading in any material respect and will not omit any material
facts or information which might reasonably be considered to be material. VMY
shall ensure that Emprise is advised on a timely basis of any material change
that may be reasonably considered relevant to this agreement.

2

TERMINATION

If accepted, this agreement between Emprise and VMY will be in
subject to termination on sixty (60) days written notice.

However, VMY may terminate this agreement without prior notice
for just cause, which shall include:

	1. 	
      Emprise committing an act of bankruptcy or becoming
      involved in any fraud or dishonest or serious misconduct in circumstances
      that would, in the reasonable opinion of VMY, make Emprise unsuitable to
      act on behalf of VMY; and/or

	 	 
	2. 	
      Emprise failing to comply with any terms of this
      agreement with such failure not being rectified within fifteen (15) days
      of receipt of notice thereof from VMY, including Emprise becoming unable
      to provide any of the required services.

Emprise may terminate this agreement without prior notice for
just cause, which shall include:

	1. 	
      VMY committing an act of bankruptcy or becoming involved
      in any fraud or dishonest or serious misconduct in circumstances that
      would, in the opinion of Emprise, make representation of VMY by Emprise
      unsuitable; and/or

	 	 
	2. 	
      VMY failing to comply with the terms of this agreement
      with such failure not being rectified within fifteen (15) days of receipt
      of notice from Emprise.

Notwithstanding the above, a breach under Disclosure of
Engagement above shall result in Emprise’s right to terminate this agreement
immediately and without notice.

If this agreement is terminated for any reason, Emprise shall
be entitled to receive, and VMY shall pay, Emprise’s fees and reimbursable
expenses to the date of termination.

SEVERABILITY

If any provision of this agreement is held invalid or
unenforceable, in whole or in part, such provision shall be ineffective to the
extent of such invalidity or unenforceability without in any manner affecting
the validity or enforceability of the remaining provisions hereof.

BINDING AGREEMENT

If you are in agreement with the terms of this proposal as
outlined herein, please indicate your agreement by signature below, at which
time this proposal shall become a binding agreement between the parties and
shall be governed by and construed in accordance with the laws of British
Columbia.

Yours very truly,

EMPRISE CAPITAL CORP

“Aron Buchman “

3

AGREED AND ACCEPTED dated this 6 day of July, 2010 on
behalf of:

Voice Mobility International, Inc

“Jay Hutton” 
__________________________________
Jay
Hutton 

4Striker Energy Corp.: Exhibit 10.7 - Filed by newsfilecorp.com

” <> “ Denotes certain parts that have not been
disclosed and have been filed separately with the Secretary, Securities and
Exchange Commission, and is subject to a confidential treatment request pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

ASSET PURCHASE AGREEMENT 

by and between 

Cypress Pharmaceuticals, Inc. 

and 

PediatRx, Inc.

Table of Contents

	  	  	Page
	Article I.
      DEFINITIONS 	     1 
	Article II.
      PURCHASE AND SALE OF ASSETS 	     6 
	           
             2.1 	Purchase and
      Sale of Assets 	     6 
	           
             2.2 	Assignability and Consents 	     6 
	           
             2.3 	License to
      Shared Know-How 	     7 
	Article III.
      ASSUMPTION OF LIABILITIES 	     7 
	Article IV.
      PURCHASE PRICE AND PAYMENT 	     7 
	           
             4.1 	Purchase
      Price 	     7 
	           
             4.2 	Allocation
      of Purchase Price 	     7 
	           
             4.3 	Payment of
      Sales, Use and Other Taxes 	     7 
	Article V.
      CLOSING 	     7 
	           
             5.1 	Time and
      Place 	     7 
	           
             5.2 	Deliveries
      at Closing 	     8 
	Article VI.
      REPRESENTATIONS AND WARRANTIES OF SELLER 	     8 
	           
             6.1 	Authority of
      Seller 	     9 
	           
             6.2 	Consents and
      Approvals. 	     9 
	           
             6.3 	Non-Contravention 	     9 
	           
             6.4 	Supply
      Agreement 	     10 
	           
             6.5 	Intellectual
      Property Rights 	     10 
	           
             6.6 	Litigation
      	     11 
	           
             6.7 	Compliance
      with Law 	     11 
	           
             6.8 	Inventory
      	     11 
	           
             6.9 	Regulatory
      Matters 	     11 
	           
             6.10 	Brokers
    	     12 
	           
             6.11 	No
      Non-Competition Agreements or Preferential Obligations 	     12 
	           
             6.12 	Financial
      Information 	     12 
	           
             6.13 	No Other
      Representations and Warranties 	     12 
	Article VII.
      REPRESENTATIONS AND WARRANTIES OF BUYER 	     12 
	           
             7.1 	Corporate
      Organization 	     12 
	           
             7.2 	Authority of
      Buyer 	     13 
	           
             7.3 	Consents and
      Approvals 	     13 
	           
             7.4 	Non-Contravention 	     13 

i

Table of Contents

	  	  	Page 
	           
             7.5 	Litigation
      	13
  
	               
         7.6 	Brokers 	14 
	           
             7.7 	Financial
      Capability 	14
  
	               
         7.8 	No Other Representations and
      Warranties 	14 
	Article VIII.
      COVENANTS OF THE PARTIES 	14
  
	               
         8.1 	[Reserved] 	14 
	           
             8.2 	Reasonable
      Best Efforts 	14
  
	               
         8.3 	Cooperation 	14 
	           
             8.4 	Access
    	14
  
	               
         8.5 	Public Announcements 	15 
	           
             8.6 	Non-Solicitation/Non-Competition 	16
  
	               
         8.7 	Corporate Names 	16 
	           
             8.8 	Assistance
      in Collecting Certain Amounts 	16
  
	               
         8.9 	[Reserved] 	16 
	           
             8.10 	Differentiation of Products 	17
  
	               
         8.11 	Regulatory Matters 	17 
	           
             8.12 	Product
      Returns 	17
  
	               
         8.13 	Further Assurances 	18 
	           
             8.14 	Transitional
      Assistance by Seller 	18
  
	               
         8.15 	Regulatory Transition by
      Seller 	18 
	           
             8.16 	Confidentiality 	18
  
	Article IX. [RESERVED] 	19 
	Article X.
      [RESERVED] 	19
  
	Article XI. INDEMNIFICATION
      	19 
	           
             11.1 	Survival of
      Representations, Warranties, Etc 	19
  
	               
         11.2 	Indemnification 	19 
	           
             11.3 	Limitations
      	22
  
	               
         11.4 	Buyer Insurance 	22 
	           
             11.5 	Seller
      Insurance 	22
  
	               
         11.6 	Remedies Exclusive 	23 
	Article XII.
      [RESERVED] 	23
  
	Article XIII. MISCELLANEOUS
      	23 

ii

Table of Contents

	 	  	Page
  
	                   13.1 	Notices
    	23 
	                   13.2 	Entire Agreement 	24 
	                   13.3 	Construction
      of Certain Terms and Phrases 	24 
	                   13.4 	Waiver 	24 
	                   13.5 	Amendment
      	24 
	                   13.6 	Third Party Beneficiaries
      	24 
	                   13.7 	Assignment;
      Binding Effect 	24 
	                   13.8 	Headings 	25 
	                   13.9 	Severability
      	25 
	                   13.10 	Governing Law 	25 
	                   13.11 	Consent to
      Jurisdiction and Forum Selection 	25 
	                   13.12 	Expenses 	25 
	                   13.13 	Counterparts
      	25 
	                   13.14 	Schedules, Exhibits and
      Other Agreements 	26 
	                   13.15 	Seller and
      Its Affiliates 	26 

iii

EXHIBITS

	A - 	Outstanding Inventory Purchase
      Order 
	B - 	Press Release 

SELLER DISCLOSURE SCHEDULE

	1.25 	Trademarks and Servicemarks
    
	4.2 	Purchase Price Allocation 
	6.2(a) 	Seller Governmental Consents  
	6.2(b) 	Required Seller Third Party Consents 
	6.2(c) 	Other Seller Third Party
      Consents 
	6.5(a) 	Registered Intellectual Property 
	6.7 	Compliance 
	6.9 	Regulatory Approvals 
	6.12 	Income Statement

BUYER DISCLOSURE SCHEDULE

	7.3 	Buyer Consents
    

iv

ASSET PURCHASE AGREEMENT

     This Asset Purchase Agreement
(this “Agreement”) is made and entered into as of the 22nd day of July, 2010
(the “Closing Date”), by and between Cypress Pharmaceuticals, Inc., a
Mississippi corporation, with principal offices located at 135 Industrial Blvd.,
Madison, MS 39110, (“Seller”) and PediatRx, Inc., a wholly-owned subsidiary of
Striker Energy Corp. and a corporation formed pursuant to the laws of the State
of Nevada, with principal offices located at 90, Fairmount Road West, Califon,
NJ, 07830 USA (“Buyer”).

RECITALS

     WHEREAS, Seller is a specialty
pharmaceutical company focused on the development and marketing of prescription
pharmaceutical products, including the product known as GranisolTM (granisetron
HCl) Oral Solution.

     WHEREAS, Buyer is a corporation
changing its business focus to a specialty pharmaceutical company focused on the
development and marketing of prescription pharmaceutical products for the
pediatric pharmaceutical marketplace.

     WHEREAS, Buyer desires to
purchase from Seller, and Seller desires to sell to Buyer, substantially all of
the assets, tangible and intangible, associated with the product known as
GranisolTM (granisetron HCl) Oral Solution on the terms set forth in this
Agreement.

     NOW, THEREFORE, in consideration
of the premises and the mutual covenants and promises contained in this
Agreement, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties agree as follows:

ARTICLE I. DEFINITIONS

     As used in this Agreement, the
following defined terms have the meanings described below:

     1.1 “Accounts Receivable”
means all trade accounts and notes receivable and other miscellaneous
receivables related to sales of the Product, including those that are not
evidenced by instruments or invoices, existing as of the Closing.

     1.2 “Action or Proceeding”
means any action, suit, proceeding, arbitration, order, inquiry, hearing,
assessment with respect to fines or penalties, or litigation (whether civil,
criminal, administrative, investigative or informal) threatened, commenced,
brought, conducted or heard by or before, or otherwise involving, any
Governmental Authority.

     1.3 “Affiliate” means,
with respect to any Person, another Person that directly, or indirectly through
one or more intermediaries, controls, is controlled by or is under common
control with such Person. “Control” and, with correlative meanings, the terms
“controlled by” and “under common control with” means the power to direct or
cause the direction of the management or policies of a Person, whether through
the ownership of voting securities, by contract, resolution, regulation or
otherwise.

     1.4 “Assets and
Properties” and “Assets or Properties” of any Person means all assets
and properties of any kind, nature, character and description (whether real,
personal or mixed, whether tangible or intangible, whether absolute, accrued,
contingent, fixed or otherwise and wherever situated), including the goodwill
related thereto, operated, owned or leased by such Person, including cash, cash
equivalents, accounts and notes receivable, chattel paper, documents,
instruments, general intangibles, real estate, equipment, inventory, goods and
intellectual property.

     1.5 “Assumed Liabilities”
means (i) all Liabilities and obligations that Buyer has expressly assumed or
agreed to assume under this Agreement; (ii) all Liabilities and obligations
under or pursuant to the Supply Agreement to be performed following the Closing
except for the purchase price due under the Outstanding Inventory Purchase
Order; (iii) Government Rebates that become payable after the Closing related
only to Product sold by the Buyer during full calendar quarters after the
Closing and a pro rata portion, determined as described below, of any Government
Rebates paid for with respect to the calendar quarter in which the Closing
occurs; (iv) Other Rebates that are submitted related only to Product sold by
the Buyer during full calendar quarters after the Closing and a pro rata
portion, determined as described below, of Other Rebates paid with respect to
the calendar quarter in which the Closing occurs; (v) Liabilities and
obligations relating to recalls or returns of Product related only to Product
sold by the Buyer after Closing; (vi) product liability claims or threatened
claims or injuries caused by the Product related only to Product sold by the
Buyer after the Closing; and (vii) other Liabilities and obligations that arise
out of or are related to the Purchased Assets (including the Regulatory
Approvals) or the Product, attributable to occurrences and circumstances arising
after the Closing. For purposes of this Section 1.5, Buyer’s pro rata share of
any Government Rebate or Other Rebate payable with respect to the calendar
quarter in which the Closing occurs will be determined based on the number of
calendar days left in the calendar quarter as of the Closing Date as a
percentage of the total number of calendar days in such calendar quarter.

     1.6 “Books and Records”
means all files, documents, instruments, papers, books and records (scientific
or financial) of Seller or an Affiliate of Seller to the extent specifically
related to the Purchased Assets or the Product, including any pricing lists,
customer lists (to the extent owned by Seller or its Affiliates), vendor lists,
financial data, regulatory information or files (including adverse event reports
and annual regulatory reports), litigation, adverse claims or demands,
investigation information or files, trademark registration certificates,
trademark renewal certificates, and other documentation relating to the
Intellectual Property, the Product or the Regulatory Approvals, but excluding
any such items (i) to the extent that any applicable Law prohibits their
transfer, (ii) to the extent that any transfer thereof would cause Seller or any
of its Affiliates to violate confidentiality provisions thereunder, or (iii)
specifically prepared by Seller for the negotiation of this Agreement.

     1.7 “Business Day” means a
day other than Saturday, Sunday or any day on which banks located in Mississippi
are authorized or obligated to close.

     1.8 “Buyer Disclosure
Schedule” has the meaning set forth in the preamble of Article VII to this
Agreement.

     1.9 “Buyer Consents” has
the meaning set forth in Section 7.3.

2

     1.10 “Closing” has the
meaning set forth in Section 5.1.

     1.11 “Closing Date” has
the meaning set forth in the first paragraph hereof.

     1.12 “Contract” means any
and all legally binding commitments, contracts, purchase orders, leases, or
other agreements, whether written or oral.

     1.13 “Corporate Names” has
the meaning set forth in Section 8.7(a) .

     1.14 “Damages” has the
meaning set forth in Section 11.2(a) .

     1.15 “Encumbrance” means
any mortgage, pledge, assessment, security interest, deed of trust, lease, lien,
adverse claim, levy, charge or other encumbrance of any kind, or any conditional
sale or title retention agreement or other agreement to give any of the
foregoing in the future.

     1.16 “Excluded Assets”
means all Assets and Properties of Seller and its Affiliates except the
Purchased Assets. The term “Excluded Assets” includes, but is not limited to
Accounts Receivables.

     1.17 “Excluded
Liabilities” means all Liabilities of Seller and its Affiliates except the
Assumed Liabilities. The term “Excluded Liabilities” includes, by example, the
following, in each case, to the extent related to Product sold by Seller or any
of its Affiliates prior to Closing: all Liabilities of Seller and its Affiliates
for chargebacks, Government Rebates or Other Rebates, except to the extent
specifically included in the definition of Assumed Liabilities, recalls and
returns, product liability claims or threatened claims or injuries caused by
Product sold by Seller or any of its Affiliates prior to the Closing and other
Liabilities and obligations that arise out of or are related to the Purchased
Assets (including the Regulatory Approvals) or the Product sold by Seller or any
of its Affiliates prior to the Closing.

     1.18 “Expiration Date”
means the date that is eighteen (18) months after the Closing Date.

     1.19 “FDA” means the
United States Food and Drug Administration.

     1.20 “Governmental
Authority” means any court, tribunal, arbitrator, authority, agency,
commission, official or other instrumentality of the United States or other
country, or any supra-national organization, state, county, city or other
political subdivision.

     1.21 “Government Rebates”
means all state and federal Medicaid/Medicare rebates related to the
Product.

     1.22 “Indemnification Claim
Notice” has the meaning set forth in Section 11.2(c) .

     1.23 “Indemnified Party”
has the meaning set forth in Section 11.2(c) .

     1.24 “Indemnitee” and
“Indemnitees” have the respective meanings set forth in Section 11.2(c)
..

3

     1.25 “Intellectual
Property“ means any and all of the following intellectual property rights
owned by or licensed to Seller and its Affiliates, to the extent primarily used
in connection with or primarily pertaining to the Product: (i) Product Know-How;
(ii) internet domain names in the United States; and (iii) the trademarks and
service marks listed in Schedule 1.25. The term Intellectual Property shall
include, without limitation, the Registered Intellectual Property.

     1.26 “Inventory” means all
inventory of finished Product owned as of the Closing by Seller or any of its
Affiliates, and any amounts delivered under the Outstanding Inventory Purchase
Order.

     1.27 “Knowledge” with
respect to any Party, means the actual knowledge of the senior executive
officers (or persons performing similar functions) of such Person, after
reasonable inquiry.

     1.28 “Law” means any
federal, state or local law, statute or ordinance, or any rule, regulation, or
published guidelines promulgated by any Governmental Authority.

     1.29 “Liability” means any
liability (whether known or unknown, asserted or unasserted, absolute or
contingent, accrued or unaccrued, liquidated or unliquidated, and due or to
become due), including any liability for Taxes.

     1.30 “Material Adverse
Effect” means an effect or condition that individually or in the aggregate
is materially adverse to (i) the Purchased Assets taken as a whole; or (ii) the
Product taken individually. An adverse matter with a value of Fifty Thousand
Dollars (US$50,000) or more shall be deemed to have a Material Adverse Effect
for purposes of this Agreement. 

     1.31 “Ordinary Course of
Business” means such action that is consistent with the past practices of
the Product.

     1.32 “Other Rebates” means
all credits, chargeback rebates, utilization based rebates, reimbursements,
refunds, discounts, allowances, returns and similar payments to wholesalers and
other distributors, buying groups, insurers and other institutions related to
the Product.

     1.33 “Other Seller Third Party
Consents” has the meaning set forth in Section 6.2(c) .

     1.34 “Outstanding Inventory
Purchase Order” shall mean the purchase order for Product attached to this
Agreement as Exhibit A.

     1.35 “Party” means each of
Buyer and Seller.

     1.36 “Permitted
Encumbrance” means any minor imperfection of title or similar Encumbrance
that individually or in the aggregate would not have a adverse effect with a
value of more than $20,000.

     1.37 “Person” means any
natural person, corporation, general partnership, limited partnership, limited
liability company, proprietorship, other business organization, trust, union,
association or Governmental Authority.

4

     1.38 “Product” shall mean
Granisol® (granisetron HCl) oral solution

     1.39 “Product Know-how”
means any and all trade secrets, know how and information to the extent owned or
controlled by Seller or any of its Affiliates and related solely to Product or
the Purchased Assets, including without limitation: (i) formulas, processes and
methods used in the manufacture of Product, included related trade secrets; (ii)
stability data, and (iii) data from clinical trials.

     1.40 “Purchase Price” has
the meaning set forth in Section 4.1.

     1.41 Purchased Assets”
means, subject to Section 2.2: (i) the Intellectual Property; (ii) the Supply
Agreement; (iii) the Books and Records; (iv) the Regulatory Approvals; (v) all
website addresses and URLs incorporating the Product’s name or trademark; (vi)
the Inventory and (vii) any other assets that are owned by Seller or any of its
Affiliates and used exclusively in connection with the manufacture, production,
packaging, distribution, marketing or sale of Product, but not including any
property, plant or equipment or other fixed assets. 

     1.42 “Registered Intellectual
Property” means all of the following Intellectual Property registered or
filed in the United States: (i) the trademarks listed on Schedule 6.5(a)
and (ii) internet domain names registered with registrars accredited by the
Internet Corporation for Assigned Names and Numbers.

     1.43 “Required Seller Third
Party Consents” has the meaning set forth in Section 6.2(b) .

     1.44 “Regulatory
Approvals” means the regulatory approvals, licenses and registrations for
Product identified in Section 6.9 of the Seller Disclosure Schedule, all
supplements thereto and the official regulatory files in Seller’s or any of its
Affiliates’ possession or control as of the Closing relating thereto.

     1.45 “Seller Disclosure
Schedule” has the meaning set forth in the preamble to Article VI of this
Agreement.

     1.46 “Seller Governmental
Consents” has the meaning set forth in Section 6.2(a) .

     1.47 “Shared Know-How”
means any and all trade secrets, know how and information to the extent owned or
controlled by Seller or any of its Affiliates, and related to (A) Product or the
Purchased Assets, and (B) other products or assets of Seller. 

     1.48 “Supply Agreement”
means a certain Single Product Manufacturing and Supply Agreement, dated as of
July 22, 2010, by and between Seller and Therapex, a division of E-Z-EM Canada
Inc. and related Quality Agreement, dated as of July 22, 2010.

5

     1.49 “Tax” means all of
the following tax in connection with the transactions contemplated hereby: (i)
any net income, alternative or add-on minimum tax, gross income, gross receipts,
sales, use, ad valorem, transfer, franchise, profits, license, excise,
severance, stamp, occupation, premium, property, environmental or windfall
profit tax, custom, duty or other tax, governmental fee or other like assessment
imposed by an governmental, regulatory or administrative entity or agency
responsible for the imposition of any such tax in the United States; (ii) any
Liability for the payment of any amounts of the type described in (i) above as a
result of being a member of any affiliated, consolidated, combined, unitary or
other group for any Taxable period; and (iii) any Liability for the payment of
any amounts of the type described in (i) or (ii) above as a result of any
express or implied obligation to indemnify any other person.

     1.50 “Third Party Claim”
has the meaning set forth in Section 11.2(d) .

     1.51 “United States” means
the United States of America, its territories and possessions.

ARTICLE II. PURCHASE AND SALE OF ASSETS

     2.1 Purchase and Sale of
Assets. Subject to the terms and conditions of this Agreement, at the
Closing, Seller shall, or shall cause its relevant Affiliates to, sell,
transfer, convey, assign and deliver to Buyer, free and clear from all
Encumbrances other than Permitted Encumbrances, and Buyer shall purchase,
acquire and accept from Seller and such Affiliates of Seller, all right, title
and interest of Seller and such Affiliates in and to the Purchased Assets.
Notwithstanding anything in this Agreement to the contrary, (i) from and after
the Closing, Seller and its Affiliates shall retain all of their right, title
and interest in and to the Excluded Assets; and (ii) Seller may retain an
archival copy of all Books and Records and other documents or materials conveyed
under this Agreement (but Seller and its Affiliates shall not use any such
archival copy for any other purposes than as an archive or as otherwise
expressly permitted under this Agreement or agreed upon in writing by
Buyer).

     2.2 Assignability and
Consents. Notwithstanding anything to the contrary contained in this
Agreement, if the sale, assignment, transfer, conveyance or delivery or
attempted sale, assignment, transfer, conveyance or delivery to Buyer of any
asset that would be a Purchased Asset is (a) prohibited by any applicable Law or
(b) would require any authorizations, approvals, consents or waivers from a
third Person or Governmental Authority and such authorizations, approvals,
consents or waivers shall not have been obtained prior to the Closing, then in
either case the Closing shall proceed without the sale, assignment, transfer,
conveyance or delivery of such asset, unless such failure to transfer such asset
would have a Material Adverse Effect, as determined by Buyer in its reasonable
discretion, and this Agreement shall not constitute a sale, assignment,
transfer, conveyance or delivery of such asset. Subject to Section 8.2, in the
event that the Closing proceeds without the sale, assignment, transfer,
conveyance or delivery of any such asset, then following the Closing, the
parties shall use their reasonable best efforts, and cooperate with each other,
to obtain promptly such authorizations, approvals, consents or waivers;
provided, however, that Seller and Buyer shall not be required to pay any
consideration to obtain any such authorization, approval, consent or waiver.
Subject to Section 8.2, pending such authorization, approval, consent or waiver,
the parties shall cooperate with each other in any mutually agreeable,
reasonable and lawful arrangements designed to provide to Buyer the benefits of use of such asset and to Seller the benefits,
including any indemnities, that, in each case, it would have obtained had the
asset been conveyed to Buyer at the Closing. If authorization, approval, consent
or waiver for the sale, assignment, transfer, conveyance or delivery of any such
asset not sold, assigned, transferred, conveyed or delivered at the Closing is
obtained, Seller shall assign, transfer, convey and deliver such asset to Buyer
at no additional cost to Buyer.

6

     2.3 License to Shared
Know-How. From and after the Closing Date, Seller hereby grants to Buyer and
its Affiliates a non-exclusive, worldwide, irrevocable and royalty-free license,
with the right to sublicense, to the Shared Know-How solely to research,
develop, make, have made, use, import, export, distribute, sell and otherwise
commercialize Product.

ARTICLE III. ASSUMPTION OF LIABILITIES

     Subject to the terms and
conditions of this Agreement, as of the Closing Date, Buyer agrees to assume,
satisfy, perform, pay and discharge the Assumed Liabilities. Seller shall retain
responsibility for and shall satisfy, perform, pay and discharge the Excluded
Liabilities.

ARTICLE IV. PURCHASE PRICE AND PAYMENT

     4.1 Purchase Price. As
consideration for the Purchased Assets, Buyer shall (i) deliver or cause to be
delivered to Seller at the Closing, an amount equal to One Million Dollars
$1,000,000 (the “Purchase Price”) in immediately available funds by wire
transfer into an account designated by Seller; and (ii) assume the Assumed
Liabilities at the Closing. If the quantity of Product delivered to Buyer under
the Outstanding Inventory Purchase Order is less than ninety percent (90%) of
the number of units ordered, then the Purchase Price shall be adjusted after
Closing by an amount calculated by subtracting the number of actual units
delivered from <> and multiplying the result by $<>.

     4.2 Allocation of Purchase
Price. The Purchase Price shall be allocated among the Purchased Assets as
set forth on Schedule 4.2 hereto. Buyer and Seller agree (a) to report the sale
and purchase of the Purchased Assets for Tax purposes in accordance with the
allocations set forth on Schedule 4.2 hereto and (b) not to take any position
inconsistent with such allocations on any of their respective tax returns.

     4.3 Payment of Sales, Use and
Other Taxes. Buyer shall be solely responsible for all sales, use, transfer,
value added and other similar Taxes, if any, typically paid by the purchaser of
personal property and arising out of the sale by Seller and its Affiliates of
the Purchased Assets to Buyer pursuant to this Agreement. For clarity, Buyer
shall have no liability for income taxes or gross receipts taxes payable by
Seller.

ARTICLE V. CLOSING

     5.1 Time and Place. The
closing of the transactions contemplated by this Agreement, including the
purchase and sale of the Purchased Assets and the assumption of the Assumed
Liabilities (the “Closing”), shall take place on the Closing Date, at the
offices of Seller, unless another place shall be agreed to by the parties.

7

5.2 Deliveries at Closing.

     (a) Closing Deliveries by
Seller. At the Closing, Seller shall deliver or cause to be delivered to
Buyer:

     (i)
physical possession of all tangible personal property included in the Purchased
Assets, which Buyer may accept and receive within sixty (60) days after the
Closing Date without incurring charges for storage, including (A) the Inventory
(which shall be delivered at the respective locations thereof at the time of the
Closing), subject to Section 8.14 below; (B) the Regulatory Approvals; and (C)
the Books and Records, and appropriate documents of transfer related thereto in
form and substance reasonably acceptable to Seller and Buyer;

     (ii) an
original Intellectual Property assignment of the Intellectual Property in form
and substance reasonably acceptable to Seller and Buyer;

     (iii)
assignment and assumption agreements, in form and substance reasonably
acceptable to Seller and Buyer, assigning to Buyer all rights and obligations of
Seller and its Affiliates under the Supply Agreement;

     (iv)
copies of all Seller Governmental Consents and Required Seller Third Party
Consents and all Other Seller Third Party Consents obtained as of Closing;
and

     (v) the
certificates and other documents to be delivered pursuant to Article X
hereof.

     (b) Closing Deliveries by
Buyer. At the Closing, Buyer will deliver or cause to be delivered to
Seller:

     (i) the
Purchase Price;

     (ii) such
instruments of assumption and other instruments or documents, in form and
substance reasonable acceptable to Seller and Buyer, as may be necessary to
effect Buyer’s assumption of the Assumed Liabilities, including, but not limited
to assumption of the Supply Agreement;

     (iii)
copies of all Buyer Consents; and

     (iv) the
certificates and other documents to be delivered pursuant to Article IX
hereof.

ARTICLE VI. REPRESENTATIONS AND WARRANTIES OF SELLER

     Subject to such exceptions as are
specifically disclosed in a disclosure schedule (referencing the appropriate
Sections hereof) attached hereto (the “Seller Disclosure Schedule”), which
Seller Disclosure Schedule shall be deemed to be representations and warranties
of Seller as if made herein, Seller represents and warrants to Buyer, as
of the date of this Agreement and as of the Closing Date, as follows:

8

     6.1 Authority of Seller.
Seller has all necessary power and authority and has taken all actions necessary
to enter into this Agreement and to carry out the transactions contemplated
hereby. This Agreement has been duly and validly executed and delivered by
Seller and, when executed and delivered by Buyer, will constitute a legal, valid
and binding obligation of Seller enforceable against it in accordance with its
terms except (a) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, and (b) as limited by laws relating
to the availability of specific performance, injunctive relief or other
equitable remedies.

     6.2 Consents and
Approvals.

     (a)
Section 6.2(a) of the Seller Disclosure Schedule sets forth a complete and
accurate list of all consents, waivers, approvals, orders or authorizations of,
or registrations, declarations or filings with, any Governmental Authority that
are required by or with respect to Seller or its Affiliates in connection with
the execution and delivery of this Agreement by Seller or the performance of its
obligations hereunder, except for such consents, waivers, approvals, orders or
authorizations the failure to obtain which, and such registrations, declarations
or filings the failure to make which, would not have a Material Adverse Effect
or materially impair or delay Seller’s ability to perform its obligations
hereunder (the “Seller Governmental Consents”).

     (b)
Section 6.2(b) of the Seller Disclosure Schedule sets forth a complete and
accurate list of all consents, waivers, approvals, or authorizations of, or
notices to, any third party (other than a Governmental Authority) that are
required by or with respect to Seller or its Affiliates in connection with the
execution and delivery of this Agreement by Seller or the performance of its
obligations hereunder, except for such consents, waivers, approvals, or
authorizations the failure to obtain which, and such notices the failure to give
which, would not have a Material Adverse Effect or materially impair or delay
Seller’s ability to perform its obligations hereunder (the “Required Seller
Third Party Consents”).

     (c)
Section 6.2(c) of the Seller Disclosure Schedule sets forth a complete and
accurate list of other consents, waivers, approvals, or authorizations of, or
notices to, any third party (other than a Governmental Authority) that are
required by or with respect to Seller or its Affiliates in connection with the
execution and delivery of this Agreement by Seller or the performance of its
obligations hereunder, which Buyer acknowledges and agrees are not material to
the Product or the Purchased Assets (the “Other Seller Third Party
Consents”).

     6.3 Non-Contravention. The
execution and delivery by Seller of this Agreement does not, and the performance
by it or its relevant Affiliates of its or their obligations under this
Agreement and the consummation of the transactions contemplated hereby will not:

9

     (a)
conflict with or result in a violation or breach of any of the terms, conditions
or provisions of the Certificate of Incorporation or By-laws or other
organizational documents of Seller or its relevant Affiliates;

     (b)
conflict with or result in a violation or breach of any term or provision of any
Law applicable to Seller, the Product, or the Purchased Assets, assuming the
receipt of all consents, waivers, approvals, orders or authorizations of
Governmental Authorities required to be obtained by Seller and the making of all
registrations, declarations or filings with Governmental Authorities required to
be made by Seller; or

     (c)
conflict with or result in a breach or default (or an event which, with notice
or lapse of time or both, would constitute a breach or default) under the Supply
Agreement, other than such conflicts, breaches or defaults as would not have an
Material Adverse Effect and assuming the receipt of all consents, waivers,
approvals, or authorizations of any third party (other than a Governmental
Authority) required to be obtained by Seller and the giving of all notices to
any third party (other than a Governmental Authority) required to be given by
Seller.

     6.4 Supply Agreement. The
Supply Agreement is the only Contract material to Seller’s manufacturing,
marketing, sale or distribution of Product in the ordinary course of business
prior to the Closing. The Supply Agreement is in effect and constitutes a legal,
valid and binding agreement, enforceable in accordance with its terms, of Seller
or an Affiliate of Seller; and Seller or an Affiliate has performed all of its
required material obligations under, and neither Seller nor any Affiliate is in
material violation or material breach of or default under, such Contract.

     6.5 Intellectual Property
Rights.

     (a)
Section 6.5(a) of the Seller Disclosure Schedule sets forth a complete and
correct list of all Registered Intellectual Property. Except as set forth in
Section 6.5(a) of the Seller Disclosure Schedule, Seller or its Affiliates own
all right, title and interest in and to, or have a license, sublicense or other
permission to use, all of the Registered Intellectual Property, free and clear
of all Encumbrances except Permitted Encumbrances. All necessary registration,
maintenance and renewal fees due in connection with such Registered Intellectual
Property have been paid and all necessary documents and certificates in
connection with such Registered Intellectual Property have been filed with the
relevant copyright, trademark or other Governmental Authorities for the purposes
of maintaining such Registered Intellectual Property.

     (b)
Seller or its Affiliates own all right, title and interest in and to all of the
Intellectual Property, free and clear of all Encumbrances except Permitted
Encumbrances.

     (c)
Neither Seller nor any of its Affiliates has received any written notice from
any Person, or has Knowledge, that the Product, infringes or misappropriates the
intellectual property rights of any third party.

     (d) All
trademarks included in the Registered Intellectual Property are the subject of
current registrations. There are no third-party rights in Seller’s current registrations relating to the Product. Seller and its
Affiliates have no Knowledge of any prior use, infringement, piracy or
counterfeiting of such trademarks, any superior rights by any third party in
such trademarks, or any adverse claims pertaining to such trademarks.

10

     6.6 Litigation. There are
no Actions or Proceedings pending or, to the Knowledge of Seller, threatened
against, relating to, affecting or arising in connection with (i) the Product;
(ii) Purchased Assets; (iii) this Agreement; or (iv) the transactions
contemplated by this Agreement. Seller is not subject to any order that could
reasonably be expected to materially impair or delay the ability of Seller to
perform its obligations under this Agreement.

     6.7 Compliance with Law.
Except as described in Section 6.7 of the Seller Disclosure Schedule, Seller and
its Affiliates have manufactured, marketed and sold the Product substantially in
compliance with all applicable Laws, except where failure to so comply would not
reasonably be expected to result in a Material Adverse Effect, and neither
Seller nor any of its Affiliates has received any written notice alleging any
violation of Laws in connection with activities related to Product.

     6.8 Inventory. To Seller’s
Knowledge, based solely on warranties made by the supplier, all of the finished
Product included in Inventory: 

     (i) were
produced or manufactured and stored in accordance with the specifications for
such Product as set forth in the applicable Regulatory Approval and
substantially in compliance with applicable Law;

     (ii) are
free from defects in processing, materials and workmanship; 

     (iii)
were manufactured, packaged, tested and stored in conformity with then-current
cGMPs; and

     (iv) are
not adulterated or misbranded within the meaning of the United States Federal
Food Drug and Cosmetic Act (21 U.S.C. Section 301 et seq.), as amended from time
to time or any other Law.

     Seller or its Affiliates at
Closing will have, and Buyer will receive at Closing or, in the case of
Inventory to be delivered under the Outstanding Inventory Purchase Order, upon
delivery of such Inventory, good and marketable title to the Inventory free and
clear of any Encumbrances. There are no inventory management agreements or
commitments related to the Product. The Outstanding Inventory Purchase Order is
the only purchase order outstanding for the Product pursuant to the Supply
Agreement.

     Seller further represents that,
since January 1, 2010, Seller and its Affiliates have not effected a price
change with respect to Product, and have not “loaded the channel” by selling
Product in a manner that is inconsistent with Seller’s normal sales channel
practices prior to January 1, 2010.

     6.9 Regulatory Matters.
All of the Regulatory Approvals are current and in full force and effect, have
been duly and validly issued, and are owned exclusively by Seller or its Affiliates. The Product is covered by a Regulatory Approval in
the United States described in Section 6.9 of the Disclosure Schedule. Seller
has not sought or obtained any Regulatory Approval for the Product, and has not
marketed or sold the Product, outside of the United States. There is no Action
or Proceeding by any Governmental Authority pending or, to the Knowledge of
Seller, threatened seeking the recall of the Product or the revocation or
suspension of any Regulatory Approval. Seller has made available to Buyer
complete and correct copies of all Regulatory Approvals. There have been no past
recalls involving the Product.

11

     6.10 Brokers. Seller has
engaged a broker in connection with the transaction contemplated by this
Agreement. Buyer will have no obligation to pay fees of any brokers, finders,
investment bankers, or financial advisors engaged by Seller in connection with
this Agreement or the transactions contemplated hereby, and such fees will be
paid by Seller.

     6.11 No Non-Competition
Agreements or Preferential Obligations. The Purchased Assets are not subject
to any non-competition agreements with, or other agreements granting
preferential rights to purchase or license the Purchased Assets to, third
parties.

     6.12 Financial
Information. The income statement related to the Purchase Assets and the
Product set forth in Schedule 6.12 hereto is true and correct in all material
respects. 

     6.13 No Other Representations
and Warranties. EXCEPT FOR THE REPRESENTATIONS OR WARRANTIES EXPRESSLY SET
FORTH IN ARTICLE VI OF THIS AGREEMENT, SELLER DISCLAIMS ALL OTHER
REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN,
INCLUDING ANY INFORMATION FURNISHED BY SELLER WITH REGARD TO THE PRODUCT, OR THE
PURCHASED ASSETS, INCLUDING THE FUTURE PROFITABILITY OF THE PRODUCT, WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT OF
INTELLECTUAL PROPERTY RIGHTS. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES
EXPRESSLY SET FORTH IN THIS ARTICLE VI, BUYER AGREES THAT SELLER SHALL NOT HAVE
ANY LIABILITY TO BUYER RESULTING FROM THE DISTRIBUTION OF OR FAILURE TO
DISTRIBUTE ANY INFORMATION TO BUYER, OR BUYER’S USE OF ANY INFORMATION,
DOCUMENTS OR MATERIALS MADE AVAILABLE TO BUYER IN ANY FORM.

ARTICLE VII. REPRESENTATIONS AND WARRANTIES OF BUYER

     Buyer represents and warrants to
Seller, as of the date hereof and as of the Closing Date, subject to such
exceptions as are specifically disclosed in the disclosure schedule (referencing
the appropriate Sections hereof) attached hereto (the “Buyer Disclosure
Schedule”), which Buyer Disclosure Schedule shall be deemed to be
representations and warranties of Buyer as if made herein, as follows:

     7.1 Corporate
Organization. Buyer is a corporation duly organized, validly existing and in
good standing under the laws of the State of Nevada and has all requisite power
and authority to own its assets and carry on its business as currently conducted
by it or as proposed to be conducted. Buyer is duly authorized to conduct its
business and is in good standing in each jurisdiction where such qualification is required, except for
any jurisdiction where failure to so qualify could not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect on Buyer or
materially impair or delay Buyer’s ability to perform its obligations
hereunder.

12

     7.2 Authority of Buyer.
Buyer has all necessary power and authority and has taken all actions necessary
to enter into this Agreement and to carry out the transactions contemplated
hereby. The Board of Directors of Buyer has taken all action required by Law,
its Certificate of Incorporation, Bylaws or otherwise to be taken by it to
authorize the execution and delivery of this Agreement by Buyer and the
consummation of the transactions contemplated hereby. This Agreement has been
duly and validly executed and delivered by Buyer and, when executed and
delivered by Seller, will constitute a legal, valid and binding obligation of
Buyer enforceable against it in accordance with its terms except (a) as limited
by applicable bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting enforcement of creditors’ rights generally; and
(b) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies.

     7.3 Consents and
Approvals. Section 7.3 of the Buyer Disclosure Schedule sets forth a
complete and accurate list of all consents, waivers, approvals, orders or
authorizations of, or registrations, declarations or filings, that are required
by Buyer in connection with the execution and delivery of this Agreement by
Buyer or the performance of its obligations hereunder, including, but not
limited to any consent of any Governmental Authority (the “Buyer Consents”).

     7.4 Non-Contravention. The
execution and delivery by Buyer of this Agreement does not, and the performance
by it of its obligations under this Agreement and the consummation of the
transactions contemplated hereby will not:

     (a)
conflict with or result in a violation or breach of any of the terms, conditions
or provisions of the Certificate of Incorporation, Bylaws or other
organizational documents of Buyer;

     (b)
assuming the receipt of all consents, waivers, approvals, orders or
authorizations of Governmental Authorities required to be obtained by Buyer and
the making of all registrations, declarations or filings with Governmental
Authorities required to be made by Buyer, conflict with or result in a violation
or breach of any term or provision of any Law applicable to Buyer; or

     (c)
conflict with or result in a breach or default (or an event which, with notice
or lapse of time or both, would constitute a breach or default) under, or result
in the termination or cancellation of, or accelerate the performance required
by, or result in the creation or imposition of any security interest, lien or
any other Encumbrance upon any Contract to which Buyer is a party or by which
Buyer or any of its assets is bound.

     7.5 Litigation. There are
no Actions or Proceedings pending, or to the Knowledge of Buyer threatened or
anticipated, against, relating to, affecting or arising in connection with (a)
this Agreement or (b) the transactions contemplated by this Agreement. Buyer is
not subject to any Order that could reasonably be expected to materially
impair or delay the ability of Buyer to perform its obligations under this
Agreement.

13

     7.6 Brokers. Buyer has not
retained any broker in connection with the transactions contemplated hereunder.
Seller will have no obligation to pay fees of any brokers, finders, investment
bankers, or financial advisors engaged by Buyer in connection with this
Agreement or the transactions contemplated hereby.

     7.7 Financial Capability.
Buyer has secured the funds to effect the Closing. 

     7.8 No Other Representations
and Warranties. EXCEPT FOR THE REPRESENTATIONS OR WARRANTIES EXPRESSLY SET
FORTH IN ARTICLE VII OF THIS AGREEMENT, BUYER DISCLAIMS ALL OTHER
REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN,
RELATED TO THIS AGREEMENT. 

ARTICLE VIII. COVENANTS OF THE PARTIES

     8.1 [Reserved]. 

     8.2 Reasonable Best
Efforts.

     (a)
Subject to Section 8.2(b) below, each of the Parties shall use its reasonable
best efforts to take, or cause to be taken, all action, or to do, or cause to be
done, all things necessary, proper or advisable under applicable Laws to
consummate and make effective the transactions contemplated by this Agreement,
including obtaining all consents and approvals of all Persons and Governmental
Authorities and removing any injunctions or other impairments or delays that are
necessary, proper or advisable to the consummation of the transactions
contemplated by this Agreement.

     (b)
Seller shall use its reasonable best efforts to obtain all Other Seller Third
Party Consents after Closing.

     8.3 Cooperation. Each
Party shall cooperate fully with the other in preparing and filing all notices,
applications, submissions, reports and other instruments and documents that are
necessary, proper or advisable under applicable Laws to consummate and make
effective the transactions contemplated by this Agreement, including Seller’s
cooperation in the efforts of Buyer to obtain any consents and approvals of any
Governmental Authority required for Buyer to be able to own the Purchased
Assets.

     8.4 Access.

     (a)
[Reserved].

     (b) Upon
the request of Seller, Buyer shall during the seven (7) year period specified in
Section 8.4(c) below following the Closing, to the extent permitted by Law,
grant to Seller and its representatives the right, during normal business hours,
to inspect and copy the Books and Records and other documents obtained from
Seller in Buyer’s possession, to the extent pertaining to
the Product or the Purchased Assets for Tax purposes and in connection with
Actions or Proceedings (except as otherwise stated in Section 8.4(c) below).

14

     (c) Buyer
agrees to keep and maintain all Books and Records and other documents obtained
from Seller in existence on the Closing Date for a period of seven (7) years and
make personnel of Buyer or its Affiliates available to Seller or its
representatives to the extent such access is reasonably related to any Excluded
Assets or otherwise necessary for Seller to comply with the terms of this
Agreement or comply with any applicable Law, subject to reasonable rules and
regulations of Buyer and any applicable Laws. Seller shall reimburse Buyer
promptly for its reasonable and necessary out of pocket expenses incurred in
complying with any request by or on behalf of Seller under the foregoing
sentence (other than the fees and costs of Buyer’s attorneys). Notwithstanding
anything in this Agreement to the contrary, Buyer and its personnel shall not be
obligated to provide access to any of Buyer’s legally privileged information or
documents under this Agreement.

     (d) Prior
to the Closing Date, Seller has cooperated with Buyer to create financial
statements related to the Product for calendar years 2008 and 2009 and for the
period of January 1, 2010 to June 30, 2010, which shall have been audited
(before Closing) by Horne, LLP. The Horne, LLP costs of this process shall be
borne by Buyer. Such income statements shall be for public filing purposes as
Buyer is a wholly-owned subsidiary of a public company, and Seller waives any
requirement or obligation of confidentiality or restrictions on public
announcements related to the preparation and use of such income statements. 

     8.5 Public Announcements.
Each of Seller and Buyer agree that, prior and subsequent to the Closing, it and
its representatives shall keep the facts surrounding the negotiation of this
Agreement and the transactions contemplated hereby, disclosures made in this
Agreement, and the results of investigations and audits conducted hereunder,
confidential and shall not disclose such information to any other Person through
a press release or otherwise (except as necessary to carry out the terms of this
Agreement or to the extent such information becomes public information or
generally available to the public through no fault of such party or its
Affiliates) without the prior written consent of the other party, unless such
party has been advised by counsel that disclosure is required to be made under
applicable Law. Notwithstanding the foregoing, Buyer and Seller agree to issue
the joint public statement announcing the Agreement in the form attached hereto
as Exhibit B on such timing as the parties may mutually agree, but,
unless the Parties otherwise mutually agree, not more than two (2) days
following the execution date. The parties also agree that each Party may issue
public statements containing substantially the same information as set forth in
Exhibit B after Closing describing Buyer’s acquisition of the Product and
consummation of the transaction. Notwithstanding anything in this Agreement to
the contrary, each party may make such disclosures as may be required by
applicable law, including applicable securities laws or listing
requirements.

15

     8.6
Non-Solicitation/Non-Competition. 

     (a) Buyer
agrees that, without the prior written consent of Seller, for a period
commencing on the date hereof and expiring on the second anniversary of the
Closing Date, Buyer will not directly or indirectly (a) induce, encourage or
solicit any officer or employee of Seller or any of its Affiliates to leave such
employment to accept any other position or employment with Buyer, or (b) assist
any Affiliate or representative of Buyer in hiring such employee; provided that
the running of newspaper advertisements, Internet postings and other means of
general distribution shall not be a violation of the foregoing. 

     (b)
Seller agrees that, for a period of ten (10) years from the Closing Date,
neither it nor any of its Affiliates, will directly or indirectly, through a
partnership, licensing arrangement or any other structure, market, sell,
distribute or otherwise make available a product that is a 5-HT3
receptor antagonist labeled as an anti-emetic in any formulation or
dosing, provided that the foregoing limitation shall not apply to a generic
version of any such product that does not contain Granisetron in any form or
presentation.

     8.7 Corporate Names.

     (a)
Except as set forth in this Section 8.7, following the Closing, Buyer shall not
have any rights by virtue of this Agreement or any of the transactions or
agreements contemplated hereby to any names, trademarks, trade names, trade
dress or logos relating to Seller or any of the Affiliates of Seller or any of
their products other than those included in the Intellectual Property (the
“Corporate Names”).

     (b) Buyer
may use for up to twelve (12) months following the Closing (or such shorter
period as any Governmental Authority shall designate), items of Inventory that
bear any of the Corporate Names, it being understood that Buyer will use its
commercially reasonable efforts to use or sell such items of Inventory prior to
selling any Product under a different trademark or trade name.

     8.8 Assistance in Collecting
Certain Amounts. From and after the Closing Date, Buyer shall assist,
cooperate with and consult with Seller and its Affiliates, at Seller’s request,
in connection with the collection of Accounts Receivable relating to products or
goods shipped or sold by Seller or its Affiliates before the Closing Date, and
Buyer shall remit promptly to Seller or the relevant Affiliate any payments or
other sums received by Buyer that relate to any sales, shipments or other
matters occurring before the Closing Date or that otherwise are properly for the
account of Seller or its Affiliates. Seller shall, and shall cause its
Affiliates to, remit promptly to Buyer any payments or other sums received by
Seller or any Affiliates after the Closing Date that relate to any sales or
shipments made by Buyer after the Closing Date and Seller shall, and shall cause
its Affiliates to, use reasonable efforts to transmit to Buyer all written
inquiries or orders, and to refer to Buyer all oral inquiries or orders,
relating to the Product (to the extent relating to operations thereof following
the Closing) that are received by Seller or any Affiliate following the Closing
Date. 

     8.9 [Reserved].

16

     8.10 Differentiation of
Products. Within sixty (60) days after the Closing, Buyer shall institute
appropriate procedures to ensure that the Product manufactured, finished or sold
by, or on behalf of, Buyer can be distinguished from the Product manufactured,
finished or sold by, or on behalf of, Seller and its Affiliates.

     8.11 Regulatory
Matters.

     (a) From
and after the transfer by Seller to Buyer of each Regulatory Approval pursuant
to the terms of this Agreement, but consistent with Sections 8.14 and 8.15
hereof, Buyer, at its cost, shall be solely responsible and liable for (i)
taking all actions, paying all fees and conducting all communication with the
appropriate Governmental Authority required by Law in respect of such Regulatory
Approval, including preparing and filing all reports (including adverse drug
experience reports) with the appropriate Governmental Authority; (ii) taking all
actions and conducting all communication with third parties in respect of the
Product sold pursuant to such Regulatory Approval (whether sold before or after
transfer of such Regulatory Approval), including responding to all complaints in
respect thereof, including complaints related to tampering or contamination; and
(iii) investigating all complaints and adverse drug experiences in respect of
the Product sold pursuant to such Regulatory Approval (whether sold before or
after transfer of such Regulatory Approval).

     (b) From
and after the transfer by Seller to Buyer of each Regulatory Approval pursuant
to the terms hereof, Seller promptly shall notify Buyer if Seller receives a
complaint or a report of an adverse drug experience in respect of a Product sold
pursuant to such Regulatory Approval. In addition, Seller shall cooperate with
Buyer’s reasonable requests and use commercially reasonable efforts to assist
Buyer in connection with the reporting, investigation of and response to any
complaint or adverse drug experience to enable Seller to meet its regulatory
reporting obligations prior to transfer by Seller to Buyer of each Regulatory
Approval, and thereafter to the extent related to a Product sold by Seller or
its Affiliates. 

     (c) From
and after the Closing Date, Buyer, at its cost, shall be solely responsible and
liable for conducting all voluntary and involuntary recalls of units of Product
sold after the Closing Date pursuant to such Regulatory Approval , including
recalls required by any Governmental Authority. Seller shall be responsible for
all costs related to any voluntary and involuntary recalls of units of the
Product sold by Seller prior to the Closing Date. Seller promptly shall notify
Buyer in the event that a recall of product sold by Seller or its Affiliates is
necessary or advisable. 

     8.12 Product Returns. From
and after the Closing Date, Buyer, at its cost, shall be solely responsible and
liable for all returns of the Product sold by Buyer after the Closing Date.
Seller shall be responsible for all costs of returns of Product sold by Seller
prior to the Closing Date.

17

     8.13 Further
Assurances.

     (a) On
and after the Closing, Seller shall from time to time, at the request of Buyer,
execute and deliver, or cause to be executed and delivered, such other
instruments of conveyance and transfer and take such other actions as Buyer may
reasonably request, in order to more effectively consummate the transactions
contemplated by this Agreement and to vest in Buyer good and marketable title to
the Purchased Assets.

     (b) On
and after the Closing, Buyer shall from time to time, at the request of Seller,
take such actions as Seller may reasonably request, in order to more effectively
consummate the transactions contemplated by this Agreement, including Buyer’s
assumption of the Assumed Liabilities.

     8.14 Transitional Assistance
by Seller. During a transitional period of up to one hundred twenty (120)
days following the Closing (or such lesser period as Buyer completes
arrangements for transfer of such distribution activities), Seller shall
maintain distribution of the Product in a manner and level of effort consistent
with the distribution activities of Seller and its Affiliates during the
calendar year 2009, and in accordance with all legal requirements. Seller shall
use Product from Buyer’s inventory for such distribution activities. Buyer shall
pay Seller, within ten (10) days after the end of each month during which Seller
provides such distribution services, an amount equal to $1,000 per month
(pro-rated for any partial month) plus Seller’s out-of-pocket costs associated
with such services.

     8.15 Regulatory Transition by
Seller. During a transitional period of up to sixty (60) days following the
Closing (or such sooner period as Buyer completes arrangements for transfer of
such regulatory activities), Seller shall assist Buyer in the maintenance of the
Regulatory Approvals of the Product and carry out the other regulatory
compliance activities required to be carried out under the Regulatory Approvals
(to the extent that such activities have not then been taken over by Buyer) in a
manner and level of effort consistent with the regulatory procedures of Seller
and its Affiliates during the calendar year 2009, and in accordance with all
legal requirements. Except as set forth in the previous sentence, all costs and
expenses for such regulatory transition services will be the responsibility of
the party incurring such costs and expenses; provided, however, that any travel
expenses incurred by Seller’s personnel in connection with providing such
services will be paid promptly by Buyer. Buyer shall provide all information and
cooperation as is reasonably requested by Seller in connection with the
activities contemplated under this Section. Buyer shall make all filings with,
and take all other actions required by, applicable Governmental Authorities that
are necessary to permit Seller to perform its obligations under this Section
8.15.

     8.16 Confidentiality. For
a period of ten (10) years following the Closing Date, Seller shall maintain the
confidentiality of all Books and Records, Product Know-How and other information
contained within the Purchased Assets that is of a confidential nature, and
shall not disclose such information to any third party without the prior written
consent of Buyer. Such obligation of confidentiality shall not apply to any
specific item of information that: (i) is now or later made known to the public
through no default by Seller or Affiliates; (ii) is acquired from a third party,
having a right to disclose such information; or (iii) is required to be
disclosed by Law, so long as Buyer is given advance notice of such
disclosure and an opportunity to seek a protective order or confidential
treatment.

18

ARTICLE IX.[RESERVED] 

ARTICLE X. [RESERVED] 

ARTICLE XI. INDEMNIFICATION

     11.1 Survival of
Representations, Warranties, Etc.. The representations and warranties of
Seller or Buyer contained in this Agreement shall survive the Closing and remain
in full force and effect until the Expiration Date. All representations and
warranties contained in this Agreement and all claims with respect thereto shall
terminate on the Expiration Date; provided that if notice of any claim for
indemnification pursuant to Section 11.2(a)(ii) or 11.2(b)(ii) shall have been
given prior to the Expiration Date and such notice describes with reasonable
specificity or description the circumstances with respect to which such
indemnification claim relates, such indemnification claim shall survive until
such time as such claim is finally resolved.

     11.2 Indemnification.

     (a) By
Seller. Subject to Section 11.3, from and after the Closing, Seller shall
indemnify, defend and hold harmless Buyer, its Affiliates, and their respective
officers, directors, employees, agents, successors and assigns from and against
any and all costs, losses, Liabilities, damages, and expenses (including
reasonable fees and disbursements of attorneys) (collectively, the “Damages”),
incurred in connection with, arising out of, resulting from or incident to (i)
any breach of any covenant or agreement of Seller under this Agreement; (ii) the
inaccuracy or breach of any representation or warranty made by Seller in this
Agreement; (iii) the Excluded Liabilities; or (iv) the marketing, distributing,
handling, sale or use of the Product prior to the Closing or the manufacture of
any Product sold prior to the Closing.

     (b) By
Buyer. Subject to Section 11.3, from and after the Closing, Buyer shall
indemnify, defend and hold harmless Seller, its Affiliates and their respective
officers, directors, employees, agents, successors and assigns from and against
any and all Damages incurred in connection with, arising out of, resulting from
or incident to (i) any breach of any covenant or agreement of Buyer under this
Agreement; (ii) the inaccuracy or breach of any representation or warranty made
by Buyer in this Agreement; (iii) the failure of Buyer to assume, pay, perform
and discharge any Assumed Liabilities or the breach of the Supply Agreement
after Closing; or (iv) the marketing, distributing, handling, sale or use of the
Product after Closing or the manufacture (whenever occurring) of any Product
sold after to the Closing.

     (c)
Procedures. The indemnified Party shall give the indemnifying Party
written notice of any Third Party Claim (defined below) (an “Indemnification
Claim Notice”) within thirty (30) days (or
such other additional period that the Indemnified Party can establish is
reasonably necessary to permit it to determine whether to make a request for
indemnification) of any Damages or discovery of fact upon which such indemnified
Party intends to base a request for indemnification under Section 11.2(a) or
Section 11.2(b), but in no event shall the indemnifying Party be liable for any
Damages that result from failure to provide such notice within such period. Each
Indemnification Claim Notice must contain a description of the claim and the
nature and amount of such Damages (to the extent that the nature and amount of
such Damages are known at such time). All indemnification claims in respect of a
Party, its Affiliates or their respective directors, officers, employees and
agents (collectively, the “Indemnitees” and each an “Indemnitee”) shall be made
solely by such Party to this Agreement (the “Indemnified Party”).

19

     (d)
Third Party Claims. The obligations of an indemnifying Party under this
Section 11.2 with respect to Damages arising from claims of any third party that
are subject to indemnification as provided for in Section 11.2(a) or Section
11.2(b) (a “Third Party Claim”) shall be governed by and be contingent upon the
following additional terms and conditions:

     (i) The
indemnified Party shall furnish promptly to the indemnifying Party copies of all
papers and official documents received in respect of any such Third Party Claim.
At its option, the indemnifying Party may assume the defense of any Third Party
Claim by giving written notice to the Indemnified Party at any time after the
indemnifying Party’s receipt of an Indemnification Claim Notice with respect to
such Third Party Claim. The assumption of the defense of a Third Party Claim by
the indemnifying Party shall be construed as an acknowledgment that the
indemnifying Party is liable to indemnify any Indemnitee for Damages in respect
of such Third Party Claim. Upon assuming the defense of a Third Party Claim, the
indemnifying Party may appoint as lead counsel in the defense of the Third Party
Claim any legal counsel selected by the indemnifying Party. In the event the
indemnifying Party assumes the defense of a Third Party Claim, the Indemnified
Party shall immediately deliver to the indemnifying Party all original notices
and documents (including court papers) received by any Indemnitee in connection
with the Third Party Claim to the extent not previously provided. Should the
indemnifying Party assume the defense of a Third Party Claim, the indemnifying
Party shall not be liable to the Indemnified Party or any other Indemnitee for
any legal expenses subsequently incurred by such Indemnified Party or other
Indemnitee in connection with the analysis, defense or settlement of the Third
Party Claim. Notwithstanding anything in this Agreement to the contrary, in the
event that it is later determined that the negligence or willful misconduct of
the Indemnified Party caused, or was a contributing cause to, the Third Party
Claim or the Damages relating thereto, the Indemnified Party shall reimburse the
indemnifying Party for the legal costs and all costs and expenses (including
attorneys’ fees and costs of suit) and any Damages, or its equitable proportion,
as the case may be, incurred by the indemnifying Party in its defense of the
Third Party Claim with respect to such Indemnitee.

20

     (ii)
Without limiting Section 11.2(d)(i), any Indemnitee shall be entitled to
participate in, but not control, the defense of such Third Party Claim and to
employ counsel of its choice for such purpose; provided, however, that such
employment shall be at the Indemnitee’s own expense unless (A) the employment
thereof has been specifically authorized by the indemnifying Party in writing,
or (B) the indemnifying Party has failed to assume the defense and employ
counsel in accordance with Section 11.2(d)(i) (in which case the Indemnified
Party shall control the defense).

     (iii)
With respect to any Damages relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnitee’s
becoming subject to injunctive or other relief or otherwise adversely affect the
business of the Indemnitee in any manner, and as to which the indemnifying Party
shall have acknowledged in writing the obligation to indemnify the Indemnitee
hereunder, the indemnifying Party shall have the sole right to consent to the
entry of any judgment, enter into any settlement or otherwise dispose of such
Damages, on such terms as the indemnifying Party, in its sole discretion, shall
deem appropriate. With respect to all other Damages in connection with Third
Party Claims, where the indemnifying Party has assumed the defense of the Third
Party Claim in accordance with Section 11.2(d)(i), the indemnifying Party shall
have authority to consent to the entry of any judgment, enter into any
settlement or otherwise voluntarily dispose of such Damages; provided that it
obtains the prior written consent of the Indemnified Party (which consent shall
not be unreasonably withheld or delayed). The indemnifying Party shall not be
liable for any settlement or other voluntary disposition of Damages by an
Indemnitee that is reached without the written consent of the indemnifying
Party. Regardless of whether the indemnifying Party chooses to defend or
prosecute any Third Party Claim, no Indemnitee shall admit any liability with
respect to, or settle, compromise or discharge, any Third Party Claim without
the prior written consent of the indemnifying Party.

     (iv)
Regardless of whether the indemnifying Party chooses to defend or prosecute any
Third Party Claim, the Indemnified Party shall, and shall cause each other
Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish
such records, information and testimony, provide such witnesses and attend such
conferences, discovery proceedings, hearings, trials and appeals as may be
reasonably requested in connection therewith. Such cooperation shall include
access during normal business hours afforded to the indemnifying Party to, and
reasonable retention by the Indemnified Party of, records and information that
are reasonably relevant to such Third Party Claim, and making Indemnitees and
other employees and agents available on a mutually convenient basis to provide
additional information and explanation of any material provided hereunder, and
the indemnifying Party shall reimburse the Indemnified Party for all its
reasonable out-of-pocket expenses in connection therewith. To the extent the
records of the Indemnitee referenced in this Section 11.2(d)(iv) are privileged
by an attorney-client relationship, the parties shall cooperate in a manner as
to preserve such privilege but to afford the indemnifying Party
with all information relevant to such Third Party Claim.

21

     11.3 Limitations. 

     (a)
Except as set forth in paragraph (c), in no event shall Seller be liable for any
Damages pursuant to Section 11.2(a) unless and until the aggregate amount of all
such Damages exceeds $50,000, in which case the Seller shall be liable for all
such Damages (from the “first dollar” and not only in excess of $50,000),
subject to paragraph (b).

     (b)
Notwithstanding Section 11.2(a), except as set forth in paragraph (c), Seller
will not be required to indemnify Buyer for Damages pursuant to Section 11.2(a)
that exceed a maximum aggregate liability of $1,000,000.

     (c) The
limitations contained in paragraphs (a) and (b) shall not apply to (i) product
liability claims arising specifically out of use of units of Product sold by
Seller prior to the Closing Date, or (ii) the Excluded Liabilities.

     (d) The
amount of any Damages under Section 11.2(a) or Section 11.2(b), as the case may
be, shall be reduced by the net amount of any insurance proceeds paid to the
Indemnified Party relating to such claim, after upward adjustment for any
insurance proceeds repayment obligations owed as a result of receipt of such
indemnification.

     (e) THE
INDEMNIFICATION OBLIGATIONS OF THE PARTIES HERETO SHALL NOT EXTEND TO SPECIAL,
EXEMPLARY OR CONSEQUENTIAL DAMAGES, INCLUDING BUSINESS INTERRUPTION OR LOST
PROFITS, OR PUNITIVE DAMAGES; PROVIDED, HOWEVER, THIS EXCLUSION IS NOT INTENDED
TO, NOR SHALL, EXCLUDE ACTUAL OR COMPENSATORY DAMAGES OF THE AFFECTED PARTY NOR
APPLY TO THIRD PARTY CLAIMS.

     11.4 Buyer Insurance.
Buyer shall maintain in effect during the five (5) year period following the
Closing Date in which Product is being marketed or sold, and for at least two
(2) years following such period of such marketing and sales, product liability
insurance with a reputable, national insurance provider, in the amount of
$2,000,000 per occurrence and $5,000,000 in aggregate, naming Seller as a named
insured, and providing for written notice to Seller in the event of a
modification or termination of such coverage. Buyer shall, at the Closing,
provide to Seller a certificate evidencing the foregoing coverage, and shall
during such period thereafter provide confirmation of such insurance at Seller’s
request.

     11.5 Seller Insurance.
Seller shall maintain in effect during the three (3) year period following the
Closing Date product liability insurance with a reputable, national insurance
provider, in the amount of $2,000,000 per occurrence and $5,000,000 in
aggregate, covering liability on sales of Product for periods prior to the
Closing Date, naming Buyer as a named insured, and providing for written notice
to Buyer in the event of a modification or termination of such coverage. Seller
shall, at the Closing, provide to Buyer a certificate evidencing the foregoing coverage, and shall during such period thereafter
provide confirmation of such insurance at Buyer’s request.

22

     11.6 Remedies Exclusive.
From and after the Closing, the remedies set forth in this Article XI shall be
exclusive and in lieu of any other remedies that may be available to the
Indemnitees pursuant to any statutory or common law with respect to any Losses
of any kind or nature incurred directly or indirectly resulting from or arising
out of any breach of this Agreement (including alleged breaches or inaccuracies
of any representation, warranty or covenant or for any alleged
misrepresentation) or the transactions contemplated hereby; provided, however,
that Buyer or Seller may seek appropriate equitable relief in a court of proper
jurisdiction. Nothing herein is intended to, nor shall be construed to, affect,
have an interpretative effect on, modify or terminate any other contract between
either party hereto or its affiliates or any rights or obligations under any
such contracts.

ARTICLE XII. [RESERVED] 

ARTICLE XIII. MISCELLANEOUS

     13.1 Notices. All notices,
requests and other communications hereunder must be in writing and will be
deemed to have been duly given only if delivered personally against written
receipt or by facsimile transmission with answer back confirmation or mailed
(postage prepaid by certified or registered mail, return receipt requested) or
by nationally recognized overnight courier that maintains records of delivery to
the parties at the following addresses or facsimile numbers:

	 	If to Buyer to: 	PediatRx, Inc. 
	 	 	c/o David Tousley  
	 	  	14610 Pawnee Street 
	 	  	Leawood, Kansas 66224 
	 	  	  
	 	With copies to: 	PediatRx, Inc. 
	 	  	90, Fairmount Road West 
	 	  	Califon, NJ, 07830 USA 
	 	  	Attention: Chief Executive Officer 
	 	  	  
	 	With copies to: 	Joe Carusone and Cameron Durrant 
	 	  	c/o Striker Energy Corporation 
	 	  	360 Bay Street, Ste 901 
	 	  	Toronto, Ontario, Canada 
	 	  	  
	 	If to Seller to: 	Cypress Pharmaceuticals, Inc. 
	 	  	135 Industrial Boulevard 
	 	  	Madison, MS 391110 
	 	  	Attention: Chief Executive Officer
  

23

All such notices, requests and other communications will (a) if
delivered personally to the address as provided in this Section, be deemed given
upon receipt, (b) if delivered by facsimile to the facsimile number as provided
in this Section, be deemed given upon receipt by the sender of the answer back
confirmation, provided a confirmation copy is sent by mail and (c) if delivered
by mail in the manner described above or by overnight courier to the address as
provided in this Section, be deemed given upon receipt. Any party from time to
time may change its address, facsimile number or other information for the
purpose of notices to that party by giving notice specifying such change to the
other party hereto in accordance with the terms of this Section.

     13.2 Entire Agreement.
This Agreement (and all Exhibits and Schedules attached hereto and all other
documents delivered in connection herewith) supersedes all prior discussions and
agreements among the parties with respect to the subject matter hereof and
contains the sole and entire agreement among the parties hereto with respect to
the subject matter hereof.

     13.3 Construction of Certain
Terms and Phrases. Unless the context of this Agreement otherwise requires:
(a) words of any gender include each other gender; (b) words using the singular
or plural number also include the plural or singular number, respectively; (c)
the terms “hereof,” “herein,” “hereby” and derivative or similar words refer to
this entire Agreement; (d) the terms “Article” or “Section” refer to the
specified Article or Section of this Agreement; (e) the term “or” has, except
where otherwise indicated, the inclusive meaning represented by the phrase
“and/or”; and (f) the term “including” or “includes” means “including without
limitation” or “includes without limitation.” Whenever this Agreement refers to
a number of days, such number shall refer to calendar days unless Business Days
are specified.

     13.4 Waiver. Any term or
condition of this Agreement may be waived at any time by the party that is
entitled to the benefit thereof, but no such waiver shall be effective unless
set forth in a written instrument duly executed by or on behalf of the party
waiving such term or condition. No waiver by any party hereto of any term or
condition of this Agreement, in any one or more instances, shall be deemed to be
or construed as a waiver of the same or any other term or condition of this
Agreement on any future occasion. All remedies, either under this Agreement or
by law or otherwise afforded, will be cumulative and not alternative.

     13.5 Amendment. This
Agreement may be amended, supplemented or modified only by a written instrument
duly executed by each party hereto.

     13.6 Third Party
Beneficiaries. The terms and provisions of this Agreement are intended
solely for the benefit of each party hereto and their respective successors or
permitted assigns and it is not the intention of the parties to confer
third-party beneficiary rights upon any other Person.

     13.7 Assignment; Binding
Effect. Neither this Agreement nor any right, interest or obligation
hereunder may be assigned by any party hereto without the prior written consent
of the other party hereto, other than to an Affiliate or to a successor in
interest of such party by reason of a merger, acquisition or sale of all or
substantially all of the assets of such party with a guarantee of performance by
the assigning party, and any attempt to do so, other than as permitted above, will be void. This Agreement is binding upon,
inures to the benefit of and is enforceable by the parties hereto and their
respective successors and permitted assigns.

24

     13.8 Headings. The
headings used in this Agreement have been inserted for convenience of reference
only and do not define or limit the provisions hereof.

     13.9 Severability. If any
provision of this Agreement is held to be illegal, invalid or unenforceable
under any present or future Law, and if the rights or obligations of any party
hereto under this Agreement will not be materially and adversely affected
thereby, (a) such provision will be fully severable, (b) this Agreement will be
construed and enforced as if such illegal, invalid or unenforceable provision
had never compromised a part hereof, (c) the remaining provisions of this
Agreement will remain in full force and effect and will not be affected by the
illegal, invalid or unenforceable provision or by its severance herefrom, and
(d) in lieu of such illegal, invalid or unenforceable provision, there will be
added automatically as a part of this Agreement a legal, valid and enforceable
provision as similar to terms to such illegal, invalid or unenforceable
provision as may be possible and reasonably acceptable to the parties.

     13.10 Governing Law. This
Agreement shall be governed by and construed in accordance with the laws of the
State of New York applicable to contracts executed and performed in such state,
without giving effect to conflicts of laws principles.

     13.11 Consent to Jurisdiction
and Forum Selection. The parties hereto agree that all actions or
proceedings arising in connection with this Agreement shall be initiated and
tried exclusively in the local and federal courts located in the State of New
York. The aforementioned choice of venue is intended by the parties to be
mandatory and not permissive in nature, thereby precluding the possibility of
litigation between the parties with respect to or arising out of this Agreement
in any jurisdiction other than that specified in this section. Each party hereby
waives any right it may have to assert the doctrine of forum non conveniens or
similar doctrine or to object to venue with respect to any proceeding brought in
accordance with this section, and stipulates that the local and federal courts
located in the State of New York shall have personal jurisdiction and venue over
each of them for purposes of litigating any dispute, controversy or proceeding
arising out of or related to this Agreement. Each party hereby authorizes and
agrees to accept service of process sufficient for personal jurisdiction in any
action against it as contemplated by this section by registered or certified
mail, return receipt requested, postage prepaid to its address for the giving of
notices as set forth in this Agreement, or in the manner set forth in Section
13.1 of this Agreement for the giving of notice. Any final judgment received
against a party in any action or proceeding shall be conclusive as to the
subject of such final judgment and may be enforced in other jurisdictions in any
manner provided by law.

     13.12 Expenses. Except as
otherwise provided in this Agreement, each party hereto shall pay its own
expenses and costs incidental to the preparation of this Agreement and to the
consummation of the transactions contemplated hereby. 

     13.13 Counterparts. This
Agreement may be executed in any number of counterparts and by facsimile, each
of which will be deemed an original, but all of which together will constitute
one and the same instrument.

25

     13.14 Schedules, Exhibits and
Other Agreements. The Exhibits, Schedules, other agreements, certificates
and notices specifically referred to in this Agreement, and delivered pursuant
hereto, are an integral part of this Agreement. Any disclosure that is made in
any of the Schedules or certificates delivered pursuant to this Agreement shall
be deemed responsive to any other applicable disclosure obligation
hereunder.

     13.15 Seller and Its
Affiliates. Seller hereby acknowledges that any reference to Seller in this
Agreement shall be to Seller and those of its Affiliates that own or possess the
Purchased Assets. Seller also agrees that any reference to action to be taken by
Seller under this Agreement shall, without further expression, include a
covenant by Seller to cause those of its Affiliates that own or possess the
Purchased Assets to take such action, as the case may be.

[Remainder of Page Intentionally Left Blank]

26

     IN WITNESS WHEREOF, this
Agreement has been executed by the Parties hereto all as of the date first above
written.

	 	Cypress Pharmaceuticals, Inc. 
	 	  	  
	 	  	  
	 	  	  
	 	By: 	/s/
      Max E. Draughn 
	 	  	Max E. Draughn 
	 		 Chief Executive
      Officer  
	 	  	  
	 	  	  
	 	PediatRx, Inc. 
	 	  	  
	 	  	  
	 	  	  
	 	By: 	/s/
      David L. Tousley 
	 		 Name: David L.
      Tousley  
	 	  	Title: Treasurer and Secretary

27

Exhibit A

Outstanding Inventory Purchase Order

 

28

Exhibit B

Form of Press Release

Release: July <>, 2010

PEDIATRX ACQUIRES GRANISOLTM

FIRST ACQUISITION FOR SPECIALTY PHARMACEUTICAL
COMPANY

CALIFON, NEW JERSEY, July <>, 2010 – PediatRx, Inc.
(“PediatRx”), a wholly owned subsidiary of Striker Energy Corp.(SKRY:OTCBB)
today announced that it has signed a definitive agreement and has completed the
acquisition of all of the assets associated with GranisolTM (granisetron HCl)
Oral Solution (“GranisolTM”) from Cypress Pharmaceuticals, Inc.

GranisolTM is used in cancer care to treat nausea and vomiting
associated with cancer therapy. GranisolTM has been approved for use by the U.S.
Food and Drug Administration and is expected to be an important source of
revenue for PediatRx.

“We are very pleased to launch our company with this product
and look forward to increasing the awareness of the strong merits of GranisolTM,”
said Dr. Cameron Durrant President and Chief Executive Officer of PediatRx.

About PediatRx, Inc.
PediatRx is a specialty
pharmaceutical company dedicated to marketing and formulating effective
therapies and supportive care products for patients hospitalized for serious
conditions including cancer. PediatRx is incorporated under the laws of the
State of Nevada, and is a wholly owned subsidiary of Striker Energy Corp.

About Striker Energy Corp.
Striker Energy Corp. is
incorporated under the laws of the State of Nevada and is publicly traded under
the symbol SKRY on the over-the-counter bulletin board.

For Further Information 

PediatRx, Inc. 
Phone:
1-866-530-5258 
Email: 

29

Forward-Looking Statements

Statements in this press
release that are not strictly historical in nature are forward-looking
statements. Words such as “expects”, “intends”, “plans”, “may”, “could”,
“should”, “anticipates”, “likely”, “believes” and words of similar import can be
used to identify forward-looking statements. Forward-looking statements are only
predictions based on current information and expectations and involve a number
of risks and uncertainties. Forward-looking statements in this press release
include statements about Striker’s expectation that, following closing, Granisol is expected to be an important source of
revenue, its plans to implement a focused-commercialization strategy and its
objective of improving awareness of Granisol in the United States. Actual events
or results may differ materially from those projected in any of such statements
due to various factors, including the risk that the infrastructure required to
implement plans to commercialize Granisol, and the risks and uncertainties
inherent in general business endeavors. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety by this
cautionary statement and Striker Energy Corp. undertakes no obligation to revise
or update this press release to reflect events or circumstances after the date
hereof.

# # #

30

Schedule 1.25 

Intellectual Property 

Granisol® trademark

31

Schedule 4.2

Purchase Price Allocation

Sales Price - $1,000,000 (subject to adjustment for actual
number of units delivered, in accordance with section 4.1, if units delivered
are less than <>) 

New Inventory - $117,180.00 (<>)

Net - $882,820.00 (Gain to Seller, product acquisition rights
(intangible asset) to Buyer) (subject to adjustment for actual number of units
delivered at $<>)

32

Schedule 6.2(a)

Seller Governmental Consents

None. 

Buyer has responsibility for obtaining a new National Drug Code
(“NDC”) and for submitting the NDC to FDA and requesting transfer to Buyer of
the Abbreviated New Drug Application (ANDA) for Product. Buyer is also
responsible for recording trademark assignments with the United States Patent
and Trademark Office.

33

Schedule 6.2(b)

Required Third Party Consents

Consent of Therapex, a division of E-Z-EM Canada Inc. to
assignment by Seller of the Supply Agreement to Buyer.

Consent of Trustmark National Bank under an Amended and
Restated Loan Agreement dated as of April 30, 2010.

Consent of Keith Pritchard (“Collateral Agent”) under a
Security Agreement between Seller and Collateral Agent on behalf of certain
noteholders, dated as of August 19, 2009.

34

Schedule 6.2(c) 

Other Seller Third Party Consents 

None.

35

Schedule 6.5(a) 

Registered Intellectual Property 

United States registered trademark 3,739,736: Granisol®

36

Schedule 6.7

Compliance

None.

37

Schedule 6.9

Regulatory Approvals

FDA-approved Abbreviated New Drug Application (ANDA) for
Product in the United States.

38

Schedule 6.12

Income Statement

Hawthorn Pharmaceutical 

Granisol Income Statement

	  	 	2010 	 	 	2009 	 	 	2008 	 
	Gross sales 	$	 117,503 	 	$	 325,600 	 	$	 803,984 	 
	Sales deductions 	 	40,211 	 	 	118,823 	 	 	313,133 	 
	Net sales 	 	77,292 	 	 	206,777 	 	 	490,851 	 
	Cost of goods sold 	 	48,243 	 	 	134,914 	 	 	311,906 	 
	Gross margin 	 	29,049 	 	 	71,863 	 	 	178,945 	 
	Development expense 	 	15,165 	 	 	45,179 	 	 	39,623 	 
	Net operating profit 	 	13,884 	 	 	26,684 	 	 	139,322 	 
	Provision for income tax 	 	5,137
    	 	 	9,873
    	 	 	51,549 	 
	Net income 	$	 8,747 	 	$	 16,811 	 	$	 87,773 	 

39

Schedule 7.3 

Buyer Consents 

None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]